Table 2. Multivariate analyses of all-patient cohorts to identify factors independently prognostic for OS in patients with advanced or metastatic gastric cancer.
| Effect/covariate included in the model | Hazard ratio | 95% confidence interval for hazard ratio | P-value |
|---|---|---|---|
| Biomarker level (median cutoff) | 1.23 | 1.01–1.49 | 0.0385 |
| ECOG performance status (⩾1 vs 0) | 1.70 | 1.39–2.07 | <0.0001 |
| Prior gastrectomy (yes vs no) | 0.60 | 0.47–0.77 | <0.0001 |
| Prior adjuvant/neoadjuvant chemotherapy (yes vs no) | 1.07 | 0.07–1.63 | 0.7582 |
| Age at randomisation (years) | 1.00 | 0.99–1.00 | 0.2946 |
| Sex (male vs female) | 1.11 | 0.90–1.37 | 0.3240 |
| Liver metastasis (yes vs no) | 1.31 | 1.04–1.65 | 0.0198 |
| Number of metastatic sites at baseline (⩾2 vs ⩽1) | 1.13 | 0.91–1.41 | 0.2613 |
| Bone metastasis at baseline (yes vs no) | 1.42 | 0.94–2.19 | 0.0977 |
| Type of gastric cancer (intestinal vs mixed) | 0.72 | 0.53–0.96 | 0.0240 |
| Type of gastric cancer (diffuse vs mixed) | 1.01 | 0.76–1.34 | 0.9539 |
Abbreviations: Ang-2=Angiopoietin-2; OS=overall survival.